Certara(US:CERT)2026-02-26 11:55Financial Performance - In 2025, the total bookings reached $482.1 million, an increase from $445.3 million in 2024 and $402.3 million in 2023[320]. - The net retention rate for 2025 was 105.3%, compared to 108.8% in 2024 and 108.4% in 2023, indicating a slight decline in customer retention[321]. - For the year ended December 31, 2025, the company reported a net loss of $1,595,000, a significant improvement from a net loss of $12,051,000 in 2024 and $55,357,000 in 2023[335]. - Adjusted EBITDA for 2025 was $134,493,000, up from $122,046,000 in 2024 and $123,108,000 in 2023, indicating a positive trend in operational performance[335]. - The company achieved total revenues of $418,838,000 for 2025, representing a 9% growth compared to 2024, with organic revenue growth of 6% amounting to $401,825,000[339]. - Adjusted net income for 2025 was $70,918,000, slightly down from $72,871,000 in 2024 but up from $69,021,000 in 2023, reflecting stable profitability[336]. - The diluted earnings per share for 2025 was $(0.01), an improvement from $(0.08) in 2024 and $(0.35) in 2023, showing a trend towards profitability[337]. - Revenue increased by $33.7 million year-over-year, contributing to the improved net income[376]. Revenue Breakdown - For the year ended December 31, 2025, total revenues increased by $33.7 million, or 9%, to $418.8 million compared to 2024, driven by strong demand for technology-enabled services and software products[364]. - Software revenue rose by $27.6 million, or 18%, to $183.3 million for the year ended December 31, 2025, primarily due to increased demand from existing customers and business acquisitions[365]. - Services revenue increased by $6.1 million, or 3%, to $235.6 million for the year ended December 31, 2025, attributed to growth in technology-enabled services[366]. Expenses and Costs - Cost of revenues increased by $6.6 million, or 4%, to $161.1 million for the year ended December 31, 2025, mainly due to higher intangible assets amortization and consulting costs[367]. - Sales and marketing expenses rose by $6.3 million, or 13%, to $53.7 million for the year ended December 31, 2025, driven by increased employee-related costs from headcount growth[368]. - Research and development expenses increased by $3.9 million, or 11%, to $41.0 million for the year ended December 31, 2025, primarily due to investments in software development and AI integration[369]. - General and administrative expenses decreased by $8.8 million, or 9%, to $85.4 million for the year ended December 31, 2025, largely due to a remeasurement change in the fair value of contingent considerations[370]. - Interest expense decreased by $1.8 million, or 8%, to $19.7 million for the year ended December 31, 2025, primarily due to a decline in market interest rates[372]. Cash Flow and Investments - Cash flow from operations for the year ended December 31, 2025, was $96.3 million, up from $80.5 million in 2024, marking a $15.9 million increase[378]. - Net cash used in investing activities decreased to $26.6 million in 2025 from $112.4 million in 2024, primarily due to a $91.3 million reduction in cash payments for business acquisitions[388]. - Net cash used in financing activities increased to $64.0 million in 2025 from $21.0 million in 2024, largely due to a $42.6 million increase in common stock repurchases[389]. Acquisitions and Market Position - The company completed three acquisitions in 2023 and 2024, including Formedix for $41.4 million and Applied BioMath for $36.6 million, enhancing its market position[351][355]. - The contingent consideration related to the Formedix acquisition was estimated at $5.2 million, with payments based on achieving revenue targets[352]. Tax and Compliance - The provision for income taxes was $9.2 million for the year ended December 31, 2025, resulting in an effective tax rate of 120.9%, compared to an income tax benefit of $5.1 million in 2024[375]. - The company recorded an income tax expense of $9.2 million for the year ended December 31, 2025, compared to an income tax benefit of $5.1 million in 2024[395]. - The company evaluates uncertain tax positions quarterly, recognizing benefits when it is more likely than not that the position will be sustained upon examination[416]. Market Opportunities and Industry Context - The pharmaceutical industry spends over $290 billion annually on R&D, with an average cost of $6.2 billion per FDA-approved drug, highlighting the significant market opportunity for biosimulation services[308]. - Regulatory acceptance of model-informed drug development is critical, with increasing recognition from authorities like the FDA and EMA driving demand for biosimulation[323]. - The competitive landscape for biosimulation products is fragmented, with factors such as model quality, regulatory acceptance, and integration capabilities being crucial for success[329]. Company Strategy and Future Outlook - The company plans to continue investing in scientific talent, sales and marketing, and research and development to support growth and expand its solutions[322]. - The company plans to expand its sales and marketing efforts to increase penetration in existing markets and attract new clients[347]. - Research and development expenses are expected to continue increasing as the company invests in enhancing software product offerings[347]. - The provision for income taxes is anticipated to rise as the company becomes more profitable over time[347]. International Operations and Currency Impact - 31% of the company's revenue for the year ended December 31, 2025, was derived from international operations[423]. - A 10% fluctuation in the U.S. dollar relative to foreign currencies could impact income from operations by approximately $3.6 million[425].